Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal Bcl-2 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Liposomal Bcl-2 siRNA (also known as nanoliposomal Bcl-2 siRNA or NL-Bcl-2 siRNA) is a preclinical RNA interference (RNAi) therapeutic candidate developed by researchers at the University of Texas MD Anderson Cancer Center. It consists of a small interfering RNA (siRNA) targeting the anti-apoptotic gene B-cell lymphoma 2 (Bcl-2), encapsulated within neutral liposomes composed of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC). Bcl-2 is overexpressed in a majority of breast cancers and contributes to chemotherapy resistance. By systemically delivering the siRNA to tumor cells, liposomal Bcl-2 siRNA downregulates Bcl-2 expression, thereby inducing both apoptotic and autophagic cell death. Preclinical studies in orthotopic mouse models of estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancers have demonstrated that systemic administration of this agent significantly inhibits tumor growth and synergistically enhances the efficacy of chemotherapeutic agents such as doxorubicin.
- Other names
- DOPC-NL-Bcl-2 siRNADOPC-NL-Bcl2 siRNADOPC-NL-Bcl 2 siRNADOPC-liposomal Bcl-2 siRNAnanoliposomal BCL2 siRNAnanoliposomal Bcl-2 siRNANL-Bcl-2 siRNANL-Bcl2 siRNANL-Bcl 2 siRNA
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on liposomal Bcl-2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal Bcl-2 siRNA.